# Conduit Pharmaceuticals

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/conduit-pharmaceuticals
Canonical HTML page: https://getbiobrief.com/entity/conduit-pharmaceuticals

## Recent coverage (1 stories)

### CDT Short Interest Climbs 70.8% as Biotech Cash Burn Erases 99.9% of Peak Value
2026-08-10 09:52:34 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Short interest in CDT Equity, the ticker for clinical-stage biotech Conduit Pharmaceuticals, jumped 70.8% after the stock plunged from a $610 high to just $0.71. With a market cap of $3.45 million and no approved products, the spike in bearish bets underscores the deep skepticism around its early-stage pipeline for autoimmune diseases and infertility.
Full story: https://getbiobrief.com/story/cdt-short-interest-biotech-penny-stock-collapse

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.